Global Blood Therapeutics Inc : Global Blood Therapeutics announces proposed public offering of common stock . Says agreement to sell $75.00 million in shares of its common stock in a registered underwritten public offering . Intends to use net proceeds from offering for development relating to its lead product candidate GBT440 .In addition, GBT has granted underwriter a 30-day option to purchase up to $11.25 million in shares of its common stock.
BioTime Inc : BioTime - Deconsolidation of Oncocyte's financial's from co's consolidated financial statements; co to report pro forma non-cash gain of about $56 million .BioTime Inc- amount of gain will be determined and recorded during quarter ending March 31, 2017.
Evotec Ag : Novo A/S becomes new long-term strategic shareholder in Evotec . It resolved on a capital increase from its authorised capital against cash . Evotec will issue 13.1 million new shares to Novo A/S .Novo A/S will invest eur 90.3 m to subscribe shares of evotec at a share price of eur 6.87 per share.
Cerecor Inc : CERECOR ENGAGES SUNTRUST ROBINSON HUMPHREY TO ASSIST WITH REVIEW OF STRATEGIC ALTERNATIVES . HAS INITIATED A PROCESS TO EXPLORE AND REVIEW A RANGE OF STRATEGIC ALTERNATIVES .SAYS STRATEGIC ALTERNATIVES THAT MAY BE EXPLORED OR EVALUATED AS PART OF THIS PROCESS INCLUDE AN ACQUISITION, MERGER, BUSINESS COMBINATION.
AB-Biotics SA : Takes ownership of 10 percent of the newly created North American company Access DX Laboratory .Access DX Laboratory was created as part of restructuring process of Ab-Biotics' client Companion DX.
Qiagen NV : Reports 2016 adjusted EPS $0.87 . Reports 2016 EPS $0.34 . Qtrly Earnings Per Share $0.04 . Qtrly adjusted EPS $0.15 . Qiagen reaffirms full-year 2017 outlook for 6-7% CER sales growth . Qiagen reports results for fourth quarter and full-year 2016 . Q4 sales $366.5 million versus I/B/E/S view $370.7 million .Reaffirms full-year 2017 outlook for adjusted EPS target before restructuring costs of $1.25-1.27 cer.
Corrects 6th and 7th bullet to say company reported, not expects 2016 adj. EPS of $0.87 and EPS of $0.34.Qiagen NV : Qiagen NV qtrly earnings per share $0.04 . Qiagen NV qtrly adjusted EPS $0.15 . Qiagen reaffirms full-year 2017 outlook for 6-7 pct CER sales growth . Reports results for fourth quarter and full-year 2016 . Q4 sales $366.5 million versus I/B/E/S view $370.7 million . Reports 2016 adjusted EPS $0.87 . Reports 2016 EPS $0.34 .Reaffirms full-year 2017 outlook for adjusted EPS target before restructuring costs of $1.25-1.27 CER.
Anhui Anke Biotechnology Group Co Ltd <300009.SZ> : Sees FY 2016 net profit to increase by 11 percent to 25 percent, or to be 26 million yuan to 29.3 million yuan . Says FY 2015 net profit was 23.4 million yuan .The reasons are turnaround of traditional coal mine business and transformation of subsidiary.
Biotest AG : Biotest to sell US therapy business to ADMA Biologics, Inc. receiving approximately 50% of the shares of ADMA Biologics, Inc . As part of transaction, biotest will contribute 11.5 million euros ($12.34 million) in cash as well as a 14 million euros loan . EBIT of continued operations is expected to improve by approx. 30 million euros in fiscal year 2016 . In addition, Biotest will contribute up to 11.5 million euros towards a future capital increase of adma on equal terms as third party investors .Transaction is expected to close during first half of 2017.
Parexel International Corp : Parexel international corp - on January 6, 2017, approved plan to restructure its operations - sec filing . Parexel international corp - restructuring initiative is company-wide . Parexel international - actions are expected to result in pre-tax charges in range of $25 - $35 million, all of which are anticipated to be cash expenditures . Parexel international-charges will include about $24 million to $32 million in employee separation costs and approximately $1 million to $3 million in other costs . Parexel international - expects to record a pre-tax charge in q3 of fiscal year ending june 30, 2017 in range of $20 million to $27 million . Co anticipates completing restructuring activities by end of fiscal year 2018 . Parexel international corp - expects charges to result in annual pre-tax savings of approximately $7 million to $10 million over course of fiscal year 2017 . Parexel international - expects to record remainder of charges to be incurred by end of fiscal year ending june 30, 2018 .Parexel international corp - expects charges to result in approximately $30 million to $40 million on an annualized basis when plans fully completed.